Kratom Makers Pivot to Pseudoindoxyl and 13-OH Analogs to Evade Pending Pennsylvania and New Jersey Bans

Why it matters

Kratom industry vendors are already reformulating products with new synthetic alkaloids to sidestep expected 7-OH bans in Pennsylvania and New Jersey, raising questions about whether current legislative language can effectively address evolving products.

The big picture

As more than a dozen states have moved to restrict 7-hydroxymitragynine (7-OH), manufacturers are pivoting to related compounds like mitragynine pseudoindoxyl and 13-OH mitragynine, which bind to opioid receptors similarly but are not yet named in proposed bans. This cat-and-mouse dynamic mirrors how synthetic cannabinoids and other gray-market drugs have historically evolved to stay ahead of regulators. Some vendors have even pivoted to entirely unrelated plants, like corydalis, that produce similar pain-killing alkaloids.

Key findings

• Vendors at the CHAMPS trade show in Atlantic City promoted new products using mitragynine pseudoindoxyl and 13-OH mitragynine, compounds chemically related to 7-OH but not explicitly named in pending bans
• One distributor launched a product derived from corydalis, a different East Asian plant with comparable alkaloids not targeted by any current legislation
• Profit margins for distributors can reach 200–300%, making it financially attractive to rapidly reformulate products
• Pennsylvania's pending bill bans products with more than 2% 7-OH plus any other semi-synthetic or chemically manipulated alkaloid — potentially the broadest state language to date
• Medical professionals warn that sweeping bans without treatment resources create withdrawal emergencies when users can no longer legally purchase products

What they say

"They can call it whatever they want," said Sen. Tracy Pennycuick (R-Montgomery County), lead sponsor of Pennsylvania's kratom bill. "If it comes up 2%, it's still banned."

Bottom line

**The kratom industry is already engineering new products to outrun state bans, exposing a fundamental challenge in regulating a rapidly evolving gray market.**